Genzyme’s Once-Daily, Oral AUBAGIO® Approved in Australia for Treatment of Relapsing Multiple Sclerosis

A new drug has been approved by the Australian Therapeutic Goods Administration (TGA). This new drug is known as Aubagio (teriflunomide) 14 mg. Aubagio is a once-daily, oral treatment for relapsing remitting forms of multiple sclerosis.

-------------------------------------------------------------------------------------------

The drug company Genzyme launched a major campaign aimed to get their new drug to be prescribed free of charge to patients with relapsing remitting multiple sclerosis (RRMS).

Each neurologist that is participating in this campaign will be able to sign up 10 patients for Aubagio, the once-daily drug.

This new drug is a powerful, but yet it's also a dangerous drug. Since Teriflunomide is such a powerful drug, it has a big gap full of serious side-effects.

“I would not trust information given by the drug company but would wait for independent assessments,” Dr Vitry told Neurology Update’s

Not only is teriflunomide a powerful and dangerous drug, it has been found that it could remain in your body for up to two years and may cause birth defects and liver damage.

Gabriel D. - Contact | Facebook


Reference: MSRC - Genzyme blitzes Australian MS market with free oral drug teriflunomide
               Neurology Update (27/11/12)